3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
18
Prostatic Neoplasms, Castration-Resistant
3
Neoplasm Metastasis
3
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration Resistant Prostate Cancer
2
Sleep Initiation and Maintenance Disorders
1
Non-metastatic Prostate Cancer
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Fatigue
1
Epilepsy
1
Depression
1
Castration-resistant Prostate Cancer
1
Brain Diseases
1
Advanced Prostate Carcinoma
1
Interventions
ziprasidone
1
enzalutamide
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Tranexamic Acid
1
Tobramycin
1
Surgical Procedures, Operative
1
Spironolactone
1
Sevelamer
1
Rocuronium
1
Registries
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Nifedipine
1
Neuropsychological Tests
1
Nafcillin
1
Molindone
1
Methylprednisolone
1
Medical Marijuana
1
Mass Screening
1
Magnetoencephalography
1
Lurasidone Hydrochloride
1
Labetalol
1
Histocompatibility Testing
1
Haloperidol
1
Fosfomycin
1
Clozapine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Epilepsy
×
enzalutamide
×
Clear all
NCT04290611
2023-04-13
VENDY
Groupe Hospitalier Pitie-Salpetriere
Completed
500,000 enrolled